- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02220049
Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors (VELDAY)
Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors
VELCADE has demonstrated marked activity in haematological cancers leading to registration (MM, MCL).
Currently only biweekly or weekly regimens have been explored. Key signalling pathways which are aberrant in haematological cancers are also present in solid tumors.
VELCADE covers a broad spectrum of proteins, which are pivotal in carcinogenesis.VELCADE as a single agent & in combination with chemotherapy in solid cancers has shown modest and real anti-tumor activity but insufficient for Phase III development.
VELCADE PK exposure may be inadequate in solid tumors compared to "liquid cancers." VELCADE daily low dose administration may allow a greater PK exposure to be achieved, which is tolerated
Hypotheses:
VELCADE daily dosing (5-days on, 2-days off) is tolerable at biologically active doses VELCADE daily dosing (5-days on, 2-days off) results in increased PK (AUC)/PD (20S proteasome inhibition) VELCADE daily dosing (5-days on, 2-days off) with increased PK/PD results in improved anti-tumor activity (Increased tolerable VELCADE AUC may potentially cross the threshold required for clinically significant anti-tumor activity in solid cancers).
Some preclinical data suggest that: VELCADE daily dosing results in increased proteasome inhibition in tumor tissues Combination of VELCADE + XRT/other daily dosing agent may have increased anti-tumor activity compared to monotherapy alone.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Gustave Roussy
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Signed written informed consent
Target population
- Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
- Ability to comply with visits/procedures required by the protocol
- Life expectancy of at least 3 months
- ECOG performance status score 0-1
- Subjects with Histologic or cytologic diagnosis of any solid tumor (nonhematologic malignancy).
- A tumor paraffin tissue block or 20-30 unstained slides from the tumor tissue block or enough slides from an FNA to allow for biomarker and predictive marker analyses. (This biopsy need not be obtained fresh at the time of screening. Obtaining unstained slides from the original diagnostic biopsy will suffice to meet this requirement).
- Measurable or evaluable disease
- Prior anti-cancer treatments are permitted (i.e. chemotherapy, radiotherapy, hormonal, or immunotherapy) with the following exceptions:
- Toxicity related to prior therapy must either have resolved, returned to baseline or been deemed irreversible but does not conflict with exclusion criteria. Peripheral pre-existent neuropathy of any grade related or not related to previous anticancer therapy is an exclusion criterion.
- At least 3 weeks must have elapsed since the last chemo-therapy, immunotherapy or radiotherapy and the beginning of protocol therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin.
- At least 3 weeks must have elapsed since the last anti-cancer hormonal therapy or antibody targeted therapy (e.g. Bevacizumab, Cetuximab, Trastuzumab). Hormonal treatment by analog LHRH will be allowed for patients with prostate cancer For extended-release formulations, the washout period must extend 1 month beyond the duration of activity of the formulation (e.g., 3 months for the activity of a depot formulation + 1 month wash out).
Age and Sex
- men and women 18 - 75
- Male and female patients of childbearing potential must use effective contraceptive measures during the study an d for at least 3 months after the end of the study treatment
Exclusion Criteria:
Sex and Reproductive Status
- Male and female patients of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to three months after the study.
- Male and female patients of childbearing potential using a prohibited contraceptive method.
- Women who are pregnant or breastfeeding.
- Women with a positive pregnancy test on enrollment or prior to study drug administration.
Target Disease Exclusions:
Subjects who have documented unstable or untreated brain metastasis for at least 4 weeks and who are still requiring steroids (Subjects with treated and stably controlled CNS metastases for at least 4 weeks and are no longer on steroids are eligible for this study).
Medical History and Concurrent Diseases
- A serious uncontrolled medical disorder or active infection, which would impair the ability of the subject to receive protocol therapy
- History of thromboembolic disease or bleeding diatheses within the last six (6) months. This includes those subjects with tumors that were known to have spontaneously bled in the past.
- History or presence of the diffuse interstitial lung disease or pericardial disease
- Previous history or current presence of neurological disorders, including epilepsy, Parkinson's disease, multiple sclerosis, stroke.
- Pre-existent peripheral neuropathy of any grade, related or unrelated to previous anticancer therapy. However, asymptomatic infraclinical neuropathy with moderate measurable changes revealed by EMG will be allowed.
- Uncontrolled or significant cardiovascular disease including
- myocardial infarction within 12 months- uncontrolled angina within 6 months
- congestive heart failure within 6 months
- LVEF ≤ 45% at baseline, or <55% if prior exposure to anthracyclines
- diagnosed or suspected congenital long QT syndrome.
- any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or "Torsade de Pointes"). Controlled atrial fibrillation is not an exclusion criterion.
- pericardial effusion
- Subjects with concomitant other malignancies (except non-melanomatous skin cancers, early stage prostate or cervical cancers) are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period
- Subjects receiving any drugs or agents that inhibit (e.g., cimetidine, erythromycin, fluoxetine, ketoconazole, paroxetine) or induce (e.g., carbamazepine, glucocorticoids, phenobarbital, rifampin) CYP2C19 or CYP3A4 within 14 days before the first dose of VELCADE
- Need for therapy with concomitant CYP 3A4 inhibitors (e.g., itraconazole,fluconazole,clarithromycin,erythromycin, norfloxacin, fluvoxamine, cimetidine, indinavir, ritonavir) or inducers (e.g., efavirenz, barbiturates, phenytoin, rifampin, glitazones)
- Green tea consummation
Physical and Laboratory Test Findings (as confirmed by repeat test/results)
- Inadequate bone marrow function defined as:
- absolute neutrophil count < 1,500 cells/mm3.
- platelet count < 100,000 cells/mm3.
- hemoglobin < 9.0 g/dl
- Inadequate hepatic function defined as:
- total bilirubin > 1.5 times the institutional upper limit of normal (IULN) unless identified as a result of a confirmed genetic disorder of bilirubin metabolism (e.g., Gilbert's syndrome or familial benign unconjugated hyperbilirubinaemia).
- alanine transaminase (ALT) and aspartate transaminase (AST) > 2.5 times the IULN
- Inadequate renal function defined as serum creatinine >1.5 times the IULN
- PT- INR/PTT >1.5 times the IULN is an exclusion criteria
- If proteinuria ≥ 1+ then quantify by urinary protein in random urine sample; eligible if <1 g/l .
- Allergies and Adverse Drug Reactions history of allergy to Velcade or chemically related compounds
- Other Exclusion Criteria:
prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Velcade
Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
|
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Identify maximum tolerated dose
Délai: Assessed every week from inclusion during the first 28 days and then every 28 days up to 19 months
|
Assessed every week from inclusion during the first 28 days and then every 28 days up to 19 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Efficacy
Délai: Assessed within 7 days of every cycle (28 days) up to 19 months
|
According to the WHO criteria for tumor response
|
Assessed within 7 days of every cycle (28 days) up to 19 months
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Rastislav BAHLEDA, MD, Gustave Roussy, Cancer Campus, Grand Paris
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2009-014354-15
- 2009/1520 (Autre identifiant: CSET number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Bortézomib
-
Columbia UniversityInconnueMésothéliomeÉtats-Unis
-
Zhongnan HospitalRecrutementLeucémie myéloïde aiguë | BortézomibChine
-
Fondazione Italiana Linfomi ONLUSComplétéMacroglobulinémie de WaldenströmItalie
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital of Guangzhou Medical UniversityInconnue
-
King Faisal Specialist Hospital & Research CenterComplété